A meta-analysis of efficacy and safety of the new a 1A -adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH YJ Wu, Q Dong, LR Liu and Q Wei BACKGROUD: Recently several clinical trials have focused on the efficacy and safety of silodosin, a new, highly selective a1A-blocker. We tried to verify silodosin's superiority to placebo and non-inferiority to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with BPH. METHODS: All randomized placebo-and active-controlled trials with silodosin were included systematically using Medline, Embase and The Cochrane Library. Primary outcome was International Prostate Symptom Score (IPSS) and IPSS subsores; secondary outcomes were peak urinary flow rate (Q max ), quality of life (QoL) and primary adverse events (AEs) included retrograde ejaculation, dizziness and headache. RESULTS: The data of the included randomized controlled trials (RCTs) were collected, extracted, and assessed by our protocol. Five RCTs including a total of 2595 patients were identified. Meta-analysis indicated that silodosin achieved significant improvement versus placebo in total IPSS, in IPSS subscores, and in Q max ; silodosin showed a greater improvement in voiding symptoms than tamsulosin, and a higher incidence of retrograde ejaculation than placebo and tamsulosin. No significant differences were observed in total IPSS, in IPSS storage symptoms, in Q max and in QoL when compared with tamsulosin. Silodosin was associated with the same low incidence of dizziness and headache with placebo and tamsulosin. CONCLUSIONS: Silodosin is an effective and well-tolerated treatment for both voiding and storage symptoms in patients with LUTS associated with BPH. Despite with increased retrograde ejaculation, its overall efficacy is not inferior to tamsulosin, while at the same time being possibly superior to tamsulosin.
INTRODUCTION
BPH is a common condition among elderly men, occurring in up to 70% of men over the age of 60 years, and in more than 90% of those aged over 80 years. 1 BPH results from a nonmalignant enlargement of the prostate caused by cellular hyperplasia of both glandular and stromal elements. 2 The enlarged prostate may occlude the lumen of the prostatic urethra, obstructing urine flow. However, the severity of BPH related with lower urinary tract symptoms (LUTS) generally does not correlate with prostate size or the extent of bladder outlet obstruction (BOO). 3, 4 The severity of symptom severity seems to be bound up with, to some extent, smooth muscle tone in the prostate and bladder neck. 4 BPH patients are treated for LUTS suggestive of BOO or so called LUTS/ BPH in clinical practice.
Existing medical therapies for LUTS/BPH include a 1 -adrenoceptor (AR) antagonists (a 1 -blockers) and 5a-reductaseinhibitors (5-ARIs), which are principally treatment option for mild to moderate cases; and surgical interventions such as TURP are for severe cases, non-resolution of symptoms with medical management and acute urinary retention etc. Studies have demonstrated that there are abundant a 1A -ARs in the prostate and the bladder neck which mediate the smooth muscle. On the other hand, a 1B -ARs are largely located on vascular smooth muscle which regulate the blood pressure and the contraction of peripheral vasculature. 5, 6 Therefore, agents with high selectivity for the a 1A subtype AR should have beneficial effects on the symptoms associated with BPH and minimal effects on blood pressure, as occurs with nonselective a-blockers.
Silodosin is a new agent with high selectivity for a 1A -ARs recently developed in Japan. In vitro studies have showed that silodosin's a 1A -to-a 1B binding ratio is extremely high (162:1), 7 which is 38 times higher than that of tamsulosin hydrochloride, 8 the effective and widely used first line a 1A -AR blockers. To date, sparse clinical studies have been performed comparing the efficacy and safety between silodosin and other a 1 -AR blockers. However, it remains unclear that wether this new a 1 -AR blocker really has its pharmacological properties and advantages over the other a 1 -AR blockers. Accordingly, here we perform a meta-analysis to test silodosin's superiority to placebo and noninferiority to tamsulosin in patients with LUTS/BPH and we try to visualize the data in such a manner that they are very easy to interpret.
MATERIALS AND METHODS

Search strategy
All randomized controlled trials (RCTs) that compare the efficacy and safety between silodosin and tamsulosin or placebo in patients with LUTS/BPH were included. A RCT was defined as a trial in which participants were assigned prospectively to one of two interventions by random allocation. All the potential articles were required to include the following terms in their titles, abstracts or keyword lists: a 1 -adrenoceptor antagonists, silodosin, BPH and LUTS.
Data extraction and quality assessment
To identify all the relevant studies, two reviewers independently searched the electronic databases Medline, Embase, The Cochrane Library, reference lists of urology textbooks, review articles, and abstracts of conference proceedings until April 2012. And they assessed selected studies, extracted and tabulated data from each article with a predefined data extraction form. Discrepancies were resolved by discussion and arbitration by a third party if necessary. The following variables were recorded: authors, year of publication, geographical region, number of patients, drug dose, prostate volume, International Prostate Symptom Score (IPSS) and its subscores, peak urinary flow rate (Q max ), quality of life (QoL) and primary adverse events (AEs) including retrograde ejaculation, dizziness and headache. When important data were not reported, we tried to contact the authors.
The reviewers assessed types of studies, concealment of allocation, completeness of follow-up and blinding of investigators, participants and outcome assessors. They screened identified titles and abstracts independently. Potentially relevant trials were retained and full text examined.
Data analysis
A formal meta-analysis was made of all RCTs comparing the efficacy and safety of silodosin treating patients with LUTS/BPH. Review Manager software (version 5.1) was used to analyze the relative risks for dichotomous data and weighted mean differences (WMDs) for continuous data, with 95% confidence intervals (CI).
When the heterogeneity appears in a meta-analysis, there are several ways to deal with it. First, do not pool the study estimates at all. Second, ignore the heterogeneity and analyze the data by fixed effect model. Third, when there is heterogeneity that cannot readily be explained, one analytical approach is to incorporate it into a random-effects model. Fourth, exclude studies and perform analyses both with and without outlying studies as part of a sensitivity analysis (See Cochrane Handbook Version 5.1.0). Here in this meta-analysis, pooled estimates of efficacy and safety were calculated using a fixed-effects model (Mantel-Haenszel) and a randomized-effects model (DerSimonian and Laird) was used according to heterogeneity. Statistical heterogeneity of treatment effects between studies was formally tested with Cochran's test for heterogeneity (Po0.1). The I 2 statistic was also examined. We explored possible sources of heterogeneity (participants, treatment, study qulity). In addition, sensitivity analysis was applied by removing individual studies from the data set and analyzing the effect on the overall results.
RESULTS
Of 22 potentially relevant studies, 16 studies were excluded after reviewing abstracts (11 studies were reviews, 5 studies were not RCTs). 6 articles were retrieved for more detailed evaluation and excluded one ongoing study with incomplete data, leaving five trials for reviewing. 9-13 3 studies 9,11,13 compared the efficacy and safety between silodosin and placebo, and 4 studies 9, 10, 12, 13 compared those between silodosin and tamsulosin. All the comparisons between silodosin and placebo were superiority design, and all the comparisons between silodosin and tamsulosin were based on a non-inferiority design.
Study characteristics
The five RCTs including 2595 participants were published in 2006-2011. The demographic and baseline characteristics of patients in the included trials were summarized in Table 1 . From this table we can see that there were almost no noticeable differences in the study populations in aspects of age, prostate volume, IPSS, Q max , and QoL. And the results for various outcome measures at 12 weeks after treatment were shown in Tables 2 and 3 . Figure 1 summarized the risks of bias of each included trials. The main limitations pertained to an inadequate description of randomization or blinding. Only two studies 11, 13 described how the random sequence was generated and allocation concealment. No studies reported the blinding of outcome assessment.
Efficacy outcomes
The results of IPSS, the primary outcome measurement, were shown in Figures 2 and 3 . The effect of silodosin outweighted the placebo in every single study, and according to the pooled estimates there were significantly greater decreases with silodosin than placebo in total symptom score (WMD À 2.92, 95% CI À 3.65 to À 2.19, Figure 2a ) and IPSS subscores (Storage WMD À 0.92, 95% CI À 1.24 to À 0.60; Voiding WMD À 1.92, 95% CI À 2.39 to À 1.44, Figures 2b and c) . On the other hand, the pooled analysis revealed that no statistically significant differences were found between silodosin and tamsulosin in total symptom score (WMD 0.15, 95% CI À 2.63 to 2.93, Figure 3a ) and storage symptom score (WMD À 0.32, 95% CI À 0.75 to 0.11, Figure 3b) , and silodosin elicited a significantly slightly greater decrease in voiding symptom score than tamsulosin did (WMD À 0.78, 95%CI À 1.48 to À 0.07, Figure 3c ). There was a significant heterogeneity (I 2 ¼ 95%) between individual trials in the comparison of silodosin and tamsulosin at the IPSS total score. Sensitivity analysis showed that the significant heterogeneity of outcome among reported trials could be attributed mainly to the trial reported by Yokoyama and colleagues. 12 For the secondary endpoint variables, silodosin achieved significant improvement at the end of treatment in Q max compared with placebo; and no significant differences were found between silodosin and tamsulosin for the mean change at 12 weeks from baseline in Q max and QoL (Table 4) . Three trials 9, 11, 13 reported on the QoL between silodosin and placebo, but meta-analysis can't be done due to unsuitable data. All the three trials reported the same results that QoL improved to a greater extent in patients receiving silodosin than in those receiving placebo. Sensitivity analysis identified the study reported by Yokoyama and colleagues 12 as the main source of heterogeneity for Q max and QoL in silodosin versus tamsulosin.
Safety outcomes
The most common treatment emergent AE was retrograde ejaculation, which was reported by 9.7-28.1% of patients who received silodosin. The combined analysis indicated that retrograde ejaculation was significantly more frequent in silodosin than in tamsulosin and placebo group. As for cardiovascular AEs, the incidences of dizziness and headache in silodosin, tamsulosin and placebo group were 2.2-7.8%, 2.9-7.3% and 0-4.7%, respectively. According to the pooled estimates, no statistically significant differences were found in the comparisons of silodosin versus tamsulosin and silodosin versus placebo (Tables 3 and 4) . Sensitivity analysis identified the study reported by Marks and colleagues 11 as the main source of heterogeneity for dizziness and headache in silodosin versus placebo.
DISCUSSION
In this systematic review we reported evidence from five placeboand active-controlled RCTs about the new highly selective a 1A -AR blocker silodosin tested in a total of 2595 patients. We evaluated the efficacy and safety of silodosin for the treatment of LUTS due to BPH. The meta-analysis proved that silodosin was an effective drug for the treatment of both storage and voiding LUTS associated with BPH because a statistically significant difference versus placebo was observed in IPSS total score, in IPSS subsores and in Q max . Meanwhile, the treatment effect of silodosin was not inferior to tamsulosin when considering the change from baseline in IPSS total score, in IPSS subsores, in Q max and in QoL due to urinary symptoms.
It is remarkable that the high selective effect of a 1A -AR blocker appeared to offer a clinically relevant benefit not only on voiding but also on storage symptoms. And in the study of Chapple et al., 13 they found that only the effect of silodosin (and not of tamsulosin) on nocturia was significantly better than that of placebo. The mechanism of this action remains to be unknown. Another noteworthy aspect is that treatment with silodosin also showed an early and rapid onset of improvement. The study of Chapple et al. 13 was a high quality research. However, the values of IPSS change from baseline to end point were presented by the adjusted means but not the standard deviation. Because standard deviation is indispensable, we can't perform a meta-analysis of continuous outcomes without this parameter. Unfortunately, we didn't include the data of this study in the primary outcomes analysis. Kawabe et al. 9 reported that there was a significant decrease in the total IPSS versus placebo in the silodosin group at 1 week, and silodosin showed a significant decrease in total IPSS versus tamsulosin at 2 weeks after treatment started. Marks and colleagues 11 found patients receiving silodosin achieved significant (Po0.0005) improvement in total IPSS, and in storage and voiding subscores at 0.5 week (i.e., 3-4 days) after treatment initiation. Mean change from baseline in Q max 2-6 h after initial dose was greater (Po0.0001) with silodosin (2.8 ± 3.4) than placebo (1.5 ± 3.8). The report suggested that significant changes can be observed at the earliest postbaseline assessments.
Kawabe et al. 14 investigated the efficacy and safety of long-term administration of silodosin in patients with LUTS associated with BPH. The results showed that statistically significant improvement in the total IPSS, in IPSS subscores, in Q max and QoL all sustained for 52 weeks from as early as week 4.
Despite its high uroselectivity, silodosin is associated with side effects. The most commonly reported treatment-emergent AEs was a reduced or absent ejaculation during orgasm (coded by the Medical Dictionary for Regulatory Activities preferred term as 'retrograde ejaculation'). The main symptoms were: orgasm, semen quantity reduced; orgasm, semen force reduced; or orgasm, no semen. This AE was the main cause of discontinuation of silodosin. It is believed that the relaxation of smooth muscle in the prostate, urethra, bladder neck, and vas deferens results in the ejaculatory disorders. 15, 16 The a 1A -adrenergic receptor is mainly expressed in the bladder neck, vas deferens, and seminal vesicles. 17 Therefore, this adverse reaction is explained by the high a 1A -adrenergic receptor subtype selectivity of silodosin. Relaxation of the prostate, urethra, and bladder neck might cause retrograde ejaculation. Our meta-analysis also revealed that silodosin led to a higher incidence of retrograde ejaculation than tamsulosin and placebo.
In addition, nonclinical studies have shown that a-adrenoceptors, particularly a 1A -adrenoceptors, are essential for the physiologic contraction of the vas deferens and hence for sperm delivery from the testes to the urethra. 18 Reduced ejaculation is caused by an impaired function of the vas deferens rather than by alterations in sperm formation, number, or function. 15 This effect does not represent a safety concern because it indicates only a reduction in semen volume that is reversible (within a few days) upon discontinuation of treatment, 16, 19 and it is not perceived as particularly bothersome (discontinuation rates due to ejaculation disorders in patients treated with silodosin were very low in the included RCTs).
The major advantage of this drug is its lack of cardiovascular side effects. It has no clinically relevant effect on blood pressure when measured either in the supine position or during orthostatic testing. 10, 13 This is important because most patients treated for LUTS associated with BPH are elderly and often on concomitant antihypertensive therapy or taking agents such as phosphodiesterase inhibitors. The heterogeneity of some variables in this study is worthy of comment. Four of thirteen variables exhibited significant heterogeneity (I 2 more than 70%). Explanations may include the following. First, the studies in our review were done in 4 regions, including Japan, Taiwan, Europe and North America. The differences in outcomes observed might reflect genetic, environmental or cultural differences among populations. Second, the standard tamsulosin dosage used in clinical practice in the USA and Europe ranges from 0.4 to 0.8 mg/day. However, three Asian trials 9,10,12 adopted the dose of tamsulosin 0.2 mg/day. Though, studies have shown that because of relatively smaller transitional zone growth and bodyweight in Asian men, low-dose tamsulosin (0.2 mg/day) is an effective treatment, and is generally well tolerated as well. [20] [21] [22] After all, the effect on outcome measures can't be overlooked. What's more, the administration of silodosin was different. The new drug was administered 4 mg twice daily in three trials, 9,10,12 while 8 mg once daily in the other two trials.
11,13
The performance bias would be produced, though the total dosage appears to be the same. Third, the number of the RCTs included is small, which has limited the ability to compare the relative efficacy of the treatments. As shown in this meta-analysis, silodosin revealed a better effect on voiding symptoms than tamsulosin, but there were only two studies included in the pooled estimate which decreased the statistical power. A final source of heterogeneity is that the trials had different inclusion-exclusion criteria and sample sizes, which brought selection bias.
With this meta-analysis of articles from the medical literature, we proved that silodosin, a highly selective a 1A -AR blocker, is an effective and safe treatment for the relief of both voiding and storage symptoms in patients with LUTS associated with benign prostatic enlargement during a period of 12 weeks. Retrograde ejaculation is the most common drug related AE, but it rarely results in discontinuation of treatment. In addition, silodosin has a low incidence of orthostatic hypotension and is associated with few events of dizziness and headache. Future research should include more high quality, rigorous randomized trials with more stringent uniformity in data reporting to draw firm conclusions. Supplementary Tables S1-S3 are original data abstraction tables collated from the studies. 
